ERBB2 and neoplasm: The pCR rates in the breast varied significantly between tumour subtypes: 66 per cent for HR–/HER2+, 42 per cent for TNBC, 41 per cent for HR+/HER2+ and 10·1 per cent for HR+/HER2– (P < 0·001).